The first-ever vaccine for treatment for Shigellosis, a type of diarrhoea, would be out in the market by next year. The Indian Council of Medical Research (ICMR) and National Institute of Cholera and Enteric Diseases (NICED) transferred the technology on April 23, 2019. Speaking to Down To Earth, lead inventor of the technology from the NICED said the institute had been working on it for 15 years. After many stages of trials, it was finally approved by ICMR for commercial production.
“It is bloody diarrhoea, that is, the stool would be accompanied with blood. It mainly affects the large intestine,” he explained. Shigellosis is recognised as a disease mainly affecting Asian and African nations. The annual incidence of shigellosis throughout the world is estimated to be 164.7 million, resulting in about 1.1 million deaths, primarily of children below five years and in the elderly…
